ahlam1399
07-22-2015, 10:59 AM
AstraZeneca drug selumetinib fails in uveal mela**ma trial
LONDON (Reuters) - AstraZeneca's much anticipated cancer drug pipeline suffered a blow on Wednesday when the experimental drug selumetinib failed to meet its goal in a late-stage trial for uveal mela**ma.
http://rc.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/rc/1/rc.img (http://rc.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/rc/1/rc.htm)
http://rc.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/rc/2/rc.img (http://rc.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/rc/2/rc.htm)
http://rc.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/rc/3/rc.img (http://rc.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/rc/3/rc.htm)
http://da.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/a2.img (http://da.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/a2.htm)
http://adchoice.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/ach.img (http://adchoice.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/ach.htm)http://pi.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/a2t.imghttp://pi2.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/a2t2.imghttp://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4853a490/sc/21/mf.gif?resize=1%2C1 http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=D1o8CnqxgIg:uOFH50AOBYY:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=D1o8CnqxgIg:uOFH50AOBYY:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=D1o8CnqxgIg:uOFH50AOBYY:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=D1o8CnqxgIg:uOFH50AOBYY:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=D1o8CnqxgIg:uOFH50AOBYY:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/D1o8CnqxgIg
LONDON (Reuters) - AstraZeneca's much anticipated cancer drug pipeline suffered a blow on Wednesday when the experimental drug selumetinib failed to meet its goal in a late-stage trial for uveal mela**ma.
http://rc.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/rc/1/rc.img (http://rc.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/rc/1/rc.htm)
http://rc.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/rc/2/rc.img (http://rc.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/rc/2/rc.htm)
http://rc.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/rc/3/rc.img (http://rc.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/rc/3/rc.htm)
http://da.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/a2.img (http://da.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/a2.htm)
http://adchoice.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/ach.img (http://adchoice.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/ach.htm)http://pi.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/a2t.imghttp://pi2.feedsportal.com/r/234565886471/u/49/f/654207/c/35217/s/4853a490/sc/21/a2t2.imghttp://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4853a490/sc/21/mf.gif?resize=1%2C1 http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=D1o8CnqxgIg:uOFH50AOBYY:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=D1o8CnqxgIg:uOFH50AOBYY:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=D1o8CnqxgIg:uOFH50AOBYY:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=D1o8CnqxgIg:uOFH50AOBYY:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=D1o8CnqxgIg:uOFH50AOBYY:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/D1o8CnqxgIg